)
Sohini Das writes on automobile and healthcare sectors for Business Standard. Over her 17 years as a journalist, she has covered multiple sectors and issues -- FMCG, dairy, tourism, and state elections, among others, across Kolkata, Ahmedabad, and Mumbai. She loves doing personality stories and ground reportage.
Sohini Das writes on automobile and healthcare sectors for Business Standard. Over her 17 years as a journalist, she has covered multiple sectors and issues -- FMCG, dairy, tourism, and state elections, among others, across Kolkata, Ahmedabad, and Mumbai. She loves doing personality stories and ground reportage.
Mixing multiple strains to get what is called a multi-variant vaccine may be a way to get better immunity, scientists feel
INSACOG expanded, ASHA workers doing man to man surveys, tracking and tracing on
Booster shot with Sputnik trials may also begin
Vaccinations and more people having already got the disease may have lowered the count.
Delays in consignments, rising prices of key ingredients worry industry
In a Q&A, Om Manchanda says the firm is now growing organically in the Southern market, but is open to inorganic opportunities there
They say mRNA vaccines could offer best protection for vulnerable children
Experts say priority should be on second dose to achieve target of vaccinating entire adult population by 2021-end
Companies may, however, report sequential drop in numbers as Q1FY22 coincided with outbreak of second Covid wave, say brokerages
The company has invested Rs 100 cr in manufacturing capex in the last one year
RDIF says Sputnik Light can act as a booster shot for even those who have been vaccinated with other vaccines like mRNA candidates
Where Gennova scores is that it has achieved to crack the stringent sub-zero temperature requirements
First Covid-19 vaccine in the world for children this young
There are several candidates in the works - the Serum Institute of India, Bharat Biotech, and Zydus Cadila are working on either developing or manufacturing anti-malarial vaccines
Non-Covid occupancies, higher average revenue per occupied bed, cost rationalisation driving growth
SEC asks J&J to monitor adverse events closely for next three months
New entrants in the largely unorganised Indian pharmaceuticals market are trying out innovative ways to tap a vast market that lies in hinterland
In a Q&A, the Chairman of Piramal Group talks about the prospects of both businesses, the rationale for the demerger and how supply side issues are impacting Indian companies
The demerger will give potential investors the option of being associated with the business of their choice
The vaccine maker added that Covaxin is the first Covid-19 vaccine to be tested in the 2-6-year age group